ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

ASND Ascendis Pharma AS

137.20
-3.90 (-2.76%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Ascendis Pharma AS ASND NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-3.90 -2.76% 137.20 16:30:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
141.96 135.1588 142.36 137.20 141.10
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
02/5/202415:01GLOBEAscendis Pharma Reports First Quarter 2024 Financial Results
25/4/202415:46GLOBEAscendis Pharma to Report First Quarter 2024 Financial..
24/4/202407:30GLOBEUnited Kingdom’s MHRA Approves YORVIPATH®..
07/3/202410:31EDGAR2Form 144 - Report of proposed sale of securities
05/3/202420:39EDGAR2Form 144 - Report of proposed sale of securities
05/3/202407:14EDGAR2Form 144 - Report of proposed sale of securities
05/3/202407:04EDGAR2Form 144 - Report of proposed sale of securities
05/3/202406:37EDGAR2Form 144 - Report of proposed sale of securities
04/3/202414:17EDGAR2Form 144 - Report of proposed sale of securities
04/3/202414:07EDGAR2Form 144 - Report of proposed sale of securities
04/3/202413:54EDGAR2Form 144 - Report of proposed sale of securities
04/3/202413:36EDGAR2Form 144 - Report of proposed sale of securities
04/3/202407:30GLOBEAscendis Pharma to Participate in the Leerink Partners..
01/3/202410:00EDGAR2Form 144 - Report of proposed sale of securities
29/2/202416:13EDGAR2Form 144 - Report of proposed sale of securities
28/2/202415:49EDGAR2Form 144 - Report of proposed sale of securities
27/2/202416:45EDGAR2Form 144 - Report of proposed sale of securities
21/2/202414:17EDGAR2Form 144 - Report of proposed sale of securities
16/2/202416:16EDGAR2Form 144 - Report of proposed sale of securities
16/2/202416:15EDGAR2Form 144 - Report of proposed sale of securities
16/2/202416:14EDGAR2Form 144 - Report of proposed sale of securities
14/2/202415:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/2/202410:40EDGAR2Form 144 - Report of proposed sale of securities
14/2/202408:17EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202415:15EDGAR2Form 20-F - Annual and transition report of foreign private..
07/2/202415:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/2/202415:01GLOBEAscendis Pharma Reports Fourth Quarter and Full Year 2023..
07/2/202407:30GLOBEAscendis Pharma to Participate in the Oppenheimer 34th..
31/1/202415:15GLOBEAscendis Pharma to Report Full Year 2023 Financial Results..
31/1/202415:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/1/202415:01GLOBEAscendis Pharma Launches 2nd TransCon™ Product: YORVIPATH®..
29/1/202407:36EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/1/202407:30GLOBENew Company Eyconis Formed to Develop Ascendis Pharma..
10/1/202415:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202407:20GLOBEVector Pharma FZCO Announce Exclusive Distribution Agreement..
08/1/202405:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202405:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/1/202416:45GLOBEAscendis Pharma Introduces Vision 2030
07/1/202413:00PRNUSSpecialised Therapeutics signs exclusive agreement with..
02/1/202405:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/12/202315:15GLOBEAscendis Pharma to Participate in the 42nd Annual J.P...
20/12/202307:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202307:30GLOBESignificant Health and Quality of Life Improvements Achieved..
19/12/202315:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/12/202307:30GLOBETransCon™ hGH (lonapegsomatropin) Achieved Statistically..
13/12/202315:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/12/202307:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/12/202307:30GLOBEFDA Accepts for Review Resubmitted NDA for TransCon PTH..
07/12/202313:53EDGAR2Form 144 - Report of proposed sale of securities
05/12/202315:20EDGAR2Form 144 - Report of proposed sale of securities

Su Consulta Reciente

Delayed Upgrade Clock